Fig. 3From: Apatinib exhibits anti-leukemia activity in preclinical models of acute lymphoblastic leukemiaApatinib shows preferential cytotoxic activity against primary adult ALL cells while sparing normal PBMCs. The percentage of apoptotic cells (Annexin V+) of primary ALL patients (a) and peripheral blood or bone marrow of healthy donors (b) after exposure to indicated doses of Apatinib for 48 h. *P < 0.05; **P < 0.01Back to article page